Natural Killer Cells -Competitive Landscape, Technology and Pipeline Analysis, 2017
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Natural Killer Cells- Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Natural Killer Cells.
This report provides information on the therapeutic development based on Natural Killer Cells mechanism of action dealing with around 40+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight’s Report also assesses the Natural Killer Cells therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 22+ active companies involved in the therapeutic development of the products.
SCOPE
DelveInsight’s, “Natural Killer Cells- Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Natural Killer Cells.
This report provides information on the therapeutic development based on Natural Killer Cells mechanism of action dealing with around 40+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight’s Report also assesses the Natural Killer Cells therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 22+ active companies involved in the therapeutic development of the products.
SCOPE
- The report provides competitive pipeline landscape of Natural Killer Cells
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for Natural Killer Cells
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Natural Killer Cells pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Natural Killer Cells and also provide company profiling
- The report also gives the information of dormant pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Complete MOA intelligence and complete understanding over therapeutics development for Natural Killer Cells
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Natural Killer Cells pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Executive Summary Snapshot Report
Executive Summary
Natural Killer Cells Overview
Analysis of NK cells based therapies
NK Cells Receptors and Shares
Percentage Share of NK Cell Based Therapeutics
Targets of Natural Killer Cells Based Therapies and Their Analysis
NK Cells Based Therapy Collaborations
Collaborations and Deal Year
Collaborations and Deal value
Licensing Agreement for future development of NK Cell Therapy
Financing details of NK cells based therapies
Companies received Grants for NK cells based therapies
Designation
Institutes involved in NK cells based therapies
Technologies Involved in NK Cells Based Therapies
Clinical trials & Completion Year
Phase III Drugs
Phase II Drugs
Phase I Drugs
Recent Trends in NK Cells Therapy
Leading Companies and their Shares in Natural Killer cells Therapeutics
Market Drivers
Market Barriers
SWOT Analysis
Pipeline Therapeutics
Therapeutics under Development by Companies
Late Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-Clinical and Discovery Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Domain
Assessment by Stage and Domain
Appendix
Report Methodology
DelveInsight Consulting Services
About DelveInsight
Contact Us
Disclaimer
Executive Summary
Natural Killer Cells Overview
Analysis of NK cells based therapies
NK Cells Receptors and Shares
Percentage Share of NK Cell Based Therapeutics
Targets of Natural Killer Cells Based Therapies and Their Analysis
NK Cells Based Therapy Collaborations
Collaborations and Deal Year
Collaborations and Deal value
Licensing Agreement for future development of NK Cell Therapy
Financing details of NK cells based therapies
Companies received Grants for NK cells based therapies
Designation
Institutes involved in NK cells based therapies
Technologies Involved in NK Cells Based Therapies
Clinical trials & Completion Year
Phase III Drugs
Phase II Drugs
Phase I Drugs
Recent Trends in NK Cells Therapy
Leading Companies and their Shares in Natural Killer cells Therapeutics
Market Drivers
Market Barriers
SWOT Analysis
Pipeline Therapeutics
Therapeutics under Development by Companies
Late Stage Products (Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-Clinical and Discovery Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Domain
Assessment by Stage and Domain
Appendix
Report Methodology
DelveInsight Consulting Services
About DelveInsight
Contact Us
Disclaimer
LIST OF TABLES
Table 1: Receptors of NK cells
Table 2:Type of NK Cells Receptors
Table 3:Targets and Number of Products
Table 4:Natural Killer Cells based therapies -Target Antigens and Companies
Table 5:Collaboration and Deal Values for NK cell therapy, 2017
Table 6: Licensing Agreement for future development of NK Cell Therapy, 2017
Table 7:Companies of NK cells based therapies financing for future developments, 2017
Table 8:Companies of NK cells received grants, 2017
Table 9: Analysis of Natural killer cells on the basis of Designation, 2017
Table 10: Institute involved in NK Cells, 2017
Table 11:Companies and their technologies for NK cell therapy, 2017
Table 12:Natural Killer Cell based therapies -Trial Completion Year, Phase, Drug and Company, 2017
Table 13:SWOT analysis of NK Cells Based Therapies, 2017
Table 14:Number of Products Under Development for Natural Killer Cells Therapies, 2017
Table 15: Number of Products under development by Companies, 2017
Table 16: Late Stage Products (Phase III and Filed), 2017
Table 17: Mid Stage Products (Phase II), 2017
Table 18: Early Stage Products (Phase I), 2017
Table 19: Pre-Clinical and Discovery Products, 2017
Table 20: Assessment by Monotherapy Products, 2017
Table 21:Assessment by Combination Products, 2017
Table 22: Assessment by Route Of Administration, 2017
Table 23:Assessment by Stage and Route Of Administration, 2017
Table 24: Assessment by Molecule Type, 2017
Table 25: Assessment by Stage and Molecule Type, 2017
Table 26:Assessment by Stage of development and Domain, 2017
Table 27:Assessment by Stage of development and Domain, 2017
Table 1: Receptors of NK cells
Table 2:Type of NK Cells Receptors
Table 3:Targets and Number of Products
Table 4:Natural Killer Cells based therapies -Target Antigens and Companies
Table 5:Collaboration and Deal Values for NK cell therapy, 2017
Table 6: Licensing Agreement for future development of NK Cell Therapy, 2017
Table 7:Companies of NK cells based therapies financing for future developments, 2017
Table 8:Companies of NK cells received grants, 2017
Table 9: Analysis of Natural killer cells on the basis of Designation, 2017
Table 10: Institute involved in NK Cells, 2017
Table 11:Companies and their technologies for NK cell therapy, 2017
Table 12:Natural Killer Cell based therapies -Trial Completion Year, Phase, Drug and Company, 2017
Table 13:SWOT analysis of NK Cells Based Therapies, 2017
Table 14:Number of Products Under Development for Natural Killer Cells Therapies, 2017
Table 15: Number of Products under development by Companies, 2017
Table 16: Late Stage Products (Phase III and Filed), 2017
Table 17: Mid Stage Products (Phase II), 2017
Table 18: Early Stage Products (Phase I), 2017
Table 19: Pre-Clinical and Discovery Products, 2017
Table 20: Assessment by Monotherapy Products, 2017
Table 21:Assessment by Combination Products, 2017
Table 22: Assessment by Route Of Administration, 2017
Table 23:Assessment by Stage and Route Of Administration, 2017
Table 24: Assessment by Molecule Type, 2017
Table 25: Assessment by Stage and Molecule Type, 2017
Table 26:Assessment by Stage of development and Domain, 2017
Table 27:Assessment by Stage of development and Domain, 2017
LIST OF FIGURES
Figure 1: Mechanism of action
Figure 2:Types of NK Cell Receptors and Share of products, 2017
Figure 3:Percentage Share of NK Cell Therapeutics, 2017
Figure 4:Target of NK cells and number of products, 2017
Figure 5:Natural Killer Cell based therapies -Number of Products (N) and Stages of Development,2017
Figure 6:NK Cells Therapy Collaborations and Deal Year, 2017
Figure 7:Collaboration and deal value, 2017
Figure 8: Financing and deal value, 2017
Figure 9:NK Cells based therapies designation and Number of Products, 2017
Figure 10: Technologies Involved in NK Cells Based Therapies with their companies, 2017
Figure 11:Natural Killer Cell based therapies-Study Completion Date, Indication and Recruitment status of Phase III Drugs, 2017
Figure 12:Natural Killer Cell based therapies-Study Completion Date, Indication and Recruitment status of Phase II Drugs, 2017
Figure 13:Natural Killer Cell based therapies- Study Completion Date, Indication and Recruitment status of Phase-I Drugs, 2017
Figure 14:Natural Killer Cell based therapies-Number of Trials (N) and Study Completion Year, 2017
Figure 15:Leading NK Cells based therapies companies and Shares, 2017
Figure 16:Number of Products under Development for Natural Killer Cells Therapies,2017
Figure 17:Late Stage Products (Phase III), 2017
Figure 18: Mid Stage Products (Phase II), 2017
Figure 19:Early Stage Products (Phase I), 2017
Figure 20:Pre-Clinical and Discovery Products, 2017
Figure 21: Assessment by Monotherapy Products,2017
Figure 22: Assessment by Combination Products, 2017
Figure 23: Assessment by Route of Administration, 2017
Figure 24: Assessment by Stage and Route of Administration, 2017
Figure 25: Assessment by Molecule Type,2017
Figure 26: Assessment by Stage and Molecule Type, 2017
Figure 27: Assessment by Domain, 2017
Figure 28:Assessmentby Stage and Domain, 2017
Figure 1: Mechanism of action
Figure 2:Types of NK Cell Receptors and Share of products, 2017
Figure 3:Percentage Share of NK Cell Therapeutics, 2017
Figure 4:Target of NK cells and number of products, 2017
Figure 5:Natural Killer Cell based therapies -Number of Products (N) and Stages of Development,2017
Figure 6:NK Cells Therapy Collaborations and Deal Year, 2017
Figure 7:Collaboration and deal value, 2017
Figure 8: Financing and deal value, 2017
Figure 9:NK Cells based therapies designation and Number of Products, 2017
Figure 10: Technologies Involved in NK Cells Based Therapies with their companies, 2017
Figure 11:Natural Killer Cell based therapies-Study Completion Date, Indication and Recruitment status of Phase III Drugs, 2017
Figure 12:Natural Killer Cell based therapies-Study Completion Date, Indication and Recruitment status of Phase II Drugs, 2017
Figure 13:Natural Killer Cell based therapies- Study Completion Date, Indication and Recruitment status of Phase-I Drugs, 2017
Figure 14:Natural Killer Cell based therapies-Number of Trials (N) and Study Completion Year, 2017
Figure 15:Leading NK Cells based therapies companies and Shares, 2017
Figure 16:Number of Products under Development for Natural Killer Cells Therapies,2017
Figure 17:Late Stage Products (Phase III), 2017
Figure 18: Mid Stage Products (Phase II), 2017
Figure 19:Early Stage Products (Phase I), 2017
Figure 20:Pre-Clinical and Discovery Products, 2017
Figure 21: Assessment by Monotherapy Products,2017
Figure 22: Assessment by Combination Products, 2017
Figure 23: Assessment by Route of Administration, 2017
Figure 24: Assessment by Stage and Route of Administration, 2017
Figure 25: Assessment by Molecule Type,2017
Figure 26: Assessment by Stage and Molecule Type, 2017
Figure 27: Assessment by Domain, 2017
Figure 28:Assessmentby Stage and Domain, 2017
